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Purpose: To investigate the clinical benefits of F18-fluorodeoxyglucose-positron emission tomography and computed to-
mography (
18F- F D G- P E T / C T )  o v e r m ul t i - d e t e c t o r  r o w C T  ( M D CT )  i n p r e o p e r at i v e  s t a g i n g  o f  ga s t r i c  c a nc e r .  Methods: 
FDG-PET/CT and MDCT were performed on 78 patients with gastric cancer pathologically diagnosed by endoscopy. The ac-
curacy of radiologic staging retrospectively was compared to pathologic result after curative resection. Results: Primary tu-
mors were detected in 51 (65.4%) patients with 
18F-FDG-PET/CT, and 47 (60.3%) patients with MDCT. Regarding detection of 
lymph node metastasis, the sensitivity of FDG-PET/CT was 51.5% with an accuracy of 71.8%, whereas those of MDCT were 
69.7% and 69.2%, respectively. The sensitivity of 
18F-FDG-PET/CT for a primary tumor with signet ring cell carcinoma was 
lower than that of 
18F-FDG-PET/CT for a primary tumor with non-signet ring cell carcinoma (35.3% vs. 73.8%, P ＜ 0.01). 
Conclusion: Due to its low sensitivity, 
18F-FDG-PET/CT alone shows no definite clinical benefit for prediction of lymph node 
metastasis in preoperative staging of gastric cancer.
Key Words: Gastric cancer, 
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INTRODUCTION
Gastric cancer remains the second most common cancer 
diagnosed in the world. It accounts for 9.9% of all new cas-
es of cancer diagnosed and is responsible for 12.1% of all 
cancer deaths [1]. Although the number of overall cancer 
deaths has declined, gastric cancer is still the leading cause 
of cancer death in Korea [2]. An essential step in managing 
gastric cancer is accurately assessing the preoperative 
stage and deciding on the adequate surgery including en-
doscopic treatment, minimal invasive surgery, and pallia-
tive operation.
However, managing gastric cancer is challenging be-
cause problems in determining treatment strategy remain 
as the prognosis has a wide range according to TNM clas-
sification [3]. There are limitations in the treatment of ad-
vanced gastric cancer (AGC) with surgery, whereas early 
gastric cancer (EGC) can be treated using minimal in-
vasive surgery including endoscopy and laparoscopy 
with the limitation of lymphadenectomy [4,5]. Traditio-
nally, computed tomography (CT) has been used for pre-
operative staging of gastric cancer. CT provides useful in-Staging of gastric cancer on 
18F-FDG-PET/CT
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formation on tumors based on anatomical structure, but 
there is a limitation in the accuracy of detection of EGC [6]. 
It was reported that the diagnostic accuracy in T staging 
can be increased using multi-detector row CT (MDCT), 
but N staging which is one of the most important prog-
nostic factor as deciding treatment strategy for EGC re-
main unsatisfactory [7,8].
Recently, Positron emission tomography (PET) using 
18F-fluorodeoxyglucose (
18F-FDG) is being widely used to 
determine status of many different cancers, considered a 
new perspective on staging approach in malignancy. This 
advanced technology more accurately displays functional 
image of cancer with altered glucose metabolism, but 
lacks precision in localizing the tumor. A combined image 
of 
18F-FDG-PET and CT (
18F-FDG-PET/CT) can provide 
additional information by using the characteristics of both 
modalities. Improved staging accuracy has been demon-
strated with the use of 
18F-FDG-PET/CT in patients with 
lung and colon cancers [9-11].
18F-FDG-PET/CT has being widely used in Korea after 
the National Health Insurance Program decided to re-
imburse 
18F-FDG-PET/CT cost in 2006 [12]. There is a pauc-
ity of data on the role of 
18F-FDG-PET/CT in the pre-
operative diagnosis of gastric cancer. The purpose of this 
study is to compare the effectiveness of 
18F-FDG-PET/CT 




A retrospective analysis of 78 preoperative 
18F-FDG- 
PET/CT and MDCT in patients with gastric cancer who 
had undergone curative gastrectomy between February 
2007 and October 2008 was performed. Informed consent 
for 
18F-FDG-PET/CT and MDCT for the purpose of pre-
operative staging of gastric cancer was obtained from all 
patients. The patients comprised 53 men and 25 women 
with a median age of 61 years (range, 32 to 85 years). All of 
these patients underwent a preoperative staging proce-
dure, including past history, physical examination, blood 
chemistry, abdominal MDCT, and esophagogastroduo-
denoscopy. 
18F-FDG-PET/CT was performed within 4 we-
eks before gastrectomy.
MDCT technique
With MDCT unit, abdominal MDCT images were 
obtained. The MDCT scanner used was a 64-detector row 
scanner (Brilliance CT 64, Philips Medical System, Cleve-
land, OH, USA). All patients were given 4 g of effervescent 
granules (Top, Taejoon Pharmaceuticals, Seoul, Korea) to 
distend the stomach wall. The patients were placed in a su-
pine position on the CT table. The acquisition volume in-
cluded the whole abdomen from the dome of the dia-
phragm to lower margin of the symphysis pubis. An 
18-gauge intravenous cannula was inserted into a vein in 
the antecubital fossa, forearm or wrist. Scanning of the ab-
domen was performed after intravenous injection with au-
tomatic power injector of 2 mL/kg of contrast medium 
(Ultravist 300, Schering, Berlin, Germany) at a flow rate of 
2 to 3.5 mL/sec, total 120 mL. The scan delay time was de-
termined by automatic bolus tracking method. The region 
of interest (ROI) was positioned at the descending aorta, at 
the level of the diaphragm. The hepatic arterial phase im-
age was started 7 seconds after the attenuation reached 200 
HU. Additional CT scan for portal phase images was start-
ed 60 seconds after the start of the contrast injection. The re-
spective scanning parameters used for 16- and 64-MDCT 
scanners were 16 × 1.5 mm and 64 × 0.625 mm collimation, 
table feed of 24 and 46 mm per gantry rotation. X-ray tube 
voltage was 120 or 140 kVp, and amperage was determined 
by automatic dose reduction protocol. Volume data of 
MDCT scan were reconstructed as 5 mm thickness at 5 mm 
intervals. Coronal reformative images were reconstructed 
on a workstation, with a thickness of 3 mm at 3 mm 
intervals. All reconstructed images were sent to picture ar-
chiving and communication system (PACS) for evaluation. 
18F-FDG-PET/CT technique
Patients were advised to fast for at least 6 hours prior to 
the intravenous injection of 5 to 6 MBq/kg of 
18F-FDG. The 
18F-FDG-PET/CT scan was obtained approximately 1 hour 
after administration of the FDG, using Biograph 6 system 
(Siemens, Knoxville, TN, USA). Seven or eight bed posi-
tions were imaged from the skull base to the mid thigh Tae Kyung Ha, et al.
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Age (yr) 0.477 0.624
  ≤60 15 (39.5) 23 (60.5) 28 (73.7) 10 (26.3)
  ＞60 12 (30.0) 28 (70.0) 27 (67.5) 13 (32.5)
Gender 0.308 1.000
  Male 16 (30.2) 37 (69.8) 37 (69.8) 16 (30.2)
  Female 11 (44.0) 14 (56.0) 18 (72.0)   7 (28.0)
Tumor location 0.080 0.067
  Upper   2 (25.0)   6 (75.0)   3 (37.5)   5 (62.5)
  Middle 15 (50.0) 15 (50.0) 21 (70.0)   9 (30.0)
  Lower 10 (25.0) 30 (75.0) 31 (77.5)   9 (22.5)
Tumor size 0.002 0.330
  ≤3.5 21 (51.2) 20 (48.8) 31 (75.6) 10 (24.4)
  ＞3.5   6 (16.2) 31 (83.8) 24 (64.9) 13 (35.1)
Depth of tumor 0.005 ＜0.001
  T1 20 (54.1) 17 (45.9) 34 (91.9)   3 (8.1)
  T2   6 (22.2) 21 (77.8) 14 (51.9) 13 (48.1)
  T3   1 (9.1) 10 (90.9)   6 (54.5)   5 (45.5)
  T4   0 (0.0)   3 (100.0)   1 (33.3)   2 (66.7)
LNM 0.003 0.001
  N0 23 (51.1) 22 (48.9) 39 (86.7)   6 (13.3)
  N1   3 (18.8) 13 (81.3)   9 (56.3)   7 (43.8)
  N2   0 (0.0)   4 (100.0)   2 (50.0)   2 (50.0)
  N3   1 (7.7) 12 (92.3)   5 (38.5)   8 (61.5)
Histology 0.005 0.016
  Non-SRC
a) 16 (26.2) 45 (73.8) 39 (63.9) 22 (36.1)
  SRC 11 (64.7)   6 (35.3) 16 (94.1)   1 (5.9)
Values are presented as number (%).
PET/CT, positron emission tomography and computed tomography; LN, lymph node; LNM, lymph node metastasis; SRC, signet ring 
carcinoma.
a)Papillary adenocarcinoma, well differentiated adenocarcinoma, moderately differentiated adenocarcinoma, poorly differentiated 
adenocarcinoma, and mucinous adenocarcinoma.
level. Patients were advised not to speak, chew, or move 
during scanning. 
CT acquisition used the following parameters: 100 mA, 
130 kVp tube voltage, helical thickness of 5 mm, and a heli-
cal pitch of 1.5:1. Using these parameters, the CT scan from 
the skull base to the mid thighs was obtained in 20 
seconds. Immediately following the CT scan, a PET emis-
sion scan was acquired from the mid thigh to the base of 
skull with an acquisition time of 2.3 minutes per bed posi-
tion based on body weight.
18F-FDG-PET/CT and MDCT image interpretation 
An experienced gastrointestinal radiologist interpreted 
the MDCT images. Transverse and coronal MDCT images 
were evaluated with PACS monitors in random order. A le-
sion was determined to be cancerous when the gastric wall 
showed a focal thickening of at least 6 mm or greater or 
when focal enhancement was seen in the gastric wall. 
Lymph nodes were considered metastatic if they were large 
than 8 mm in the short-axis diameter and oval [13-15]. 
FDG uptake lesions of gastric wall and of lymph node 
bearing areas, regardless of size detected on PET/CT were 
regarded as malignancy, and the maximum standardized 
uptake value (SUVmax) was obtained using volume ROI. 
Operation
All patients underwent total gastrectomy (n = 19, 24.3%) 
or subtotal gastrectomy (n = 59, 75.7%) and standard lym-
phadenectomy (at least D2 lymphadenectomy). The ad-
vanced gastric cancer in 41 patients and EGC in 37 patients Staging of gastric cancer on 
18F-FDG-PET/CT
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Fig. 1. Correlation analysis curve between primary tumor 
maximum standardized uptake value (SUVmax) and lymph node 
(LN) SUVmax.






Primary tumor in EGC 17/37 (45.9) 10/37 (27.0) 0.039
Primary tumor in AGC 34/41 (82.9) 37/41 (90.2) 0.508
LNM in EGC   0/37 (0.0)   1/37 (2.7) NA
LNM in AGC 17/41 (41.5) 22/41 (53.7) 0.125
Values are presented as number/total number (%).
18F-FDG-PET/CT, F18-fluorodeoxyglucose-positron emission tomo-
graphy and computed tomography; MDCT, multi-detector row CT;
EGC, early gastric cancer; AGC, advanced gastric cancer; LNM, 
lymph node metastasis; NA, not available.
a)Chi-square McNemar test. 
were revealed by pathologic diagnosis. According to the 
World Health Organization classification with Japanese 
modification [16], histopathological type of primary tu-
mor was categorized as papillary adenocarcinoma (n = 1, 
1.3%), well-differentiated adenocarcinoma (n = 4, 5.1%), 
moderately differentiated adenocarcinoma (n = 31, 39.7%), 
poorly differentiated adenocarcinoma (n = 22, 28.3%), mu-
cinous adenocarcinoma (n = 3, 3.8%), and signet ring cell 
carcinoma (SRC) (n = 17, 21.8%).
Statistical analysis
We conducted Fisher’s exact test for comparing the dif-
ference of respective categorical variables. The relation be-
tween SUVmax and pTNM stage was determined using 
Kruskall-Wallis test. The sensitivity and specificity of 
18F-FDG-PET/CT and MDCT were calculated and com-
pared using McNemar’s chi-square test. The correlation 
analysis was performed to determine the relationship be-
tween tumor SUVmax and lymph node SUVmax, and also be-
tween tumor SUVmax and tumor size. P-values less than 
0.05 were considered to be significant. The statistical anal-
ysis was carried out by the SPSS ver. 18.0 (SPSS Inc., 
Chicago, IL, USA). 
RESULTS
Fifty one primary tumors were detected by pre-
operative 
18F-FDG-PET/CT, and 27 patients had no notice-
able results in 
18F-FDG-PET/CT. Tumor size, depth of tu-
mor, and lymph node metastasis (LNM) significantly af-
fected the detection of primary tumor by 
18F-FDG- 
PET/CT. As tumor size, depth of tumor, and LNM in-
creased, the primary tumor was revealed more frequently 
by 
18F-FDG-PET/CT. The detection rate of 
18F-FDG- 
PET/CT for SRC was relatively lower than that for 
non-SRC (35.3% vs. 73.8%, P = 0.005). 
18F-FDG-PET/CT de-
tected LNM in 23 patients, and 55 patients showed no sig-
nificant SUVmax of lymph node which was considered as 
metastasis. The results of 
18F-FDG-PET/CT in detecting 
LNM were similar to the results of 
18F-FDG-PET/CT in de-
tecting primary tumor; however, tumor size had no associ-
ation with detection of LNM on 
18F-FDG-PET/CT (Table 1).
The correlation analysis showed a positive correlation 
exist between SUVmax of primary tumor and that of meta-
static lymph node (P = 0.05, R = 0.43) (Fig. 1). However, 
there was no significant correlation between SUVmax of 
primary tumor and tumor size.
When assessed using the Kruskall-Wallis test, the mean 
SUVmax of primary tumor showed no significant difference 
between pT1, pT2, pT3, and pT4 (6.0 ± 1.4, 6.3 ± 0.6, 6.2 ± 0.8, and 
5.4 ± 1.7). In addition, there was no statistical difference of the 
mean SUVmax of metastatic lymph node between pN0, pN1, 
pN2, and pN3 (1.8 ± 0.5, 3.1 ± 0.9, 5.6 ± 3.8, and 2.4 ± 0.5).
The detection rate of primary tumor by 
18F-FDG- PET/CT 
and MDCT showed no significant difference. Among the 37 
patients with EGC, 
18F-FDG-PET/CT preoperatively de-
tected 17 patients who were suspected to have gastric Tae Kyung Ha, et al.
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Table 3. The sensitivity, specificity, PPV, NPV, and accuracy of PET/CT and CT for LNM in gastric cancer
Sensitivity Specificity PPV  NPV Accuracy
CT PET/CT CT PET/CT CT PET/CT CT PET/CT CT PET/CT
EGC 20.0   0.0 78.1 85.3 12.5   0.0 86.2 85.3 70.2 78.4
(1/5) (0/5) (25/32) (29/32) (1/8) (0/3) (25/29) (29/34) (26/37) (29/37)
A G C7 8 . 66 0 . 74 6 . 27 6 . 9 7 5 . 98 5 . 05 0 . 04 7 . 67 0 . 26 5 . 9
(22/28) (17/28) (6/13) (10/13) (22/29) (17/20) (6/12) (10/21) (26/37) (27/41)
T o t a l6 9 . 75 1 . 57 5 . 68 6 . 7 6 2 . 27 3 . 97 5 . 67 0 . 96 9 . 27 1 . 8
(23/33) (17/33) (31/45) (39/45) (23/37) (17/23) (31/41) (39/55) (54/78) (56/78)
Values are presented as % (number/total number).
PPV, positive predictive value; NPV, negative predictive value; PET/CT, positron emission tomography and computed tomography; LNM,
lymph node metastasis; EGC, early gastric cancer; AGC, advanced gastric cancer.
Fig. 2. Early gastric cancer in a 47-year-old man. Miaximum intensity projection image of (A) positron emission tomography (PET) and (B) 
axial PET scan demonstrate focal hypermetabolic lesion in gastric antrum (black arrow) with maximum standardized uptake value (SUVmax)
of 4.3. (C) PET/CT scan shows focal hypermtabolic intraluminal mass in posterior wall of gastric antrum (white arrow). 
cancers. However, MDCT detected only 10 patients out of 37. 
The other 10 gastric cancer patients had no measurable le-
sions on both 
18F-FDG-PET/CT and MDCT. A statistical dif-
ference between the detection rate of 
18F-FDG-PET/CT and 
that of MDCT in patients with EGC was found (45.9% vs. 
27.0%, P = 0.039). However, there was no significant differ-
ence between the detection rate of 
18F-FDG-PET/CT (34/41 
patients) and that of MDCT (37/41 patients) in AGC (Table 2). 
The SUVmax of primary tumor between EGC and AGC dis-
played similar result (6.0 ± 6.1, range 1.5 to 27.0 vs. 6.2 ± 2.9, 
range 2.2 to 13.2). However, the result of 
18F-FDG-PET/CT (17 
of 78 patients) for LNM confirmed pathologically was not 
significantly different from that of MDCT (23 of 78 patients) 
with respect to the detection of LNM (21.8% vs. 29.5%, P = 
0.07). In 41 patients with AGC, MDCT revealed 22 LNM com-
pared to 17 LNM on FDG-PET/CT (53.7% vs. 39.0%, P = 
0.125). In EGC, detection rate of 
18F-FDG-PET/CT (0 of 37 pa-
tients) for LNM did not show significant difference from that 
of MDCT (1 of 37 patients).
Overall, the accuracy of 
18F-FDG-PET/CT was similar to 
that of MDCT in the diagnosis of LNM in gastric cancer 
(71.8% vs. 69.2%). However, the sensitivity of MDCT was 
superior to that of 
18F-FDG-PET/CT (69.7% vs. 51.5%, P = 
0.035). 
18F-FDG-PET/CT was also superior to MDCT in 
terms of the specificity (86.7% vs. 75.6%, P = 0.029) (Table 3).
DISCUSSION
MDCT has also been widely used in the preoperative di-Staging of gastric cancer on 
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agnosis of gastric cancer, providing high-resolution ana-
tomic details about staging, but is limited by the use of size 
criteria [17]. FDG-PET lacks accurate anatomical ori-
entation when displaying metabolic information of malig-
nancy [18]. The combination of PET and CT has emerged 
as the most accurate technology and provides good ana-
tomical localization of functional data [19]. 
18F-FDG-PET/CT is increasingly used in the pre-
operative diagnosis of various cancers to determine stag-
ing, as well as in the detection of recurrence after curative 
surgery [9]. And recently, for the purpose of the detection 
of recurrence for gastric cancer after curative gastrectomy, 
18F-FDG-PET/CT has been introduced and shown com-
parable results to CT [20]. As shown in this study, the per-
formance of 
18F-FDG-PET/CT was comparable to that of 
MDCT with a similar 71.8% accuracy. The interesting re-
sult of 
18F-FDG-PET/CT over MDCT in this study was an 
improvement in the detection of EGC (45.9% vs. 27.0%), 
while there was no significant difference of SUVmax be-
tween EGC and AGC (6.0 ± 6.1 vs. 6.2 ± 2.9). The metabolic 
alteration of tumor allowed 
18F-FDG-PET/CT to detect le-
sion regardless of tumor advancement (Fig. 2).
In the present study, the detection rate of primary tumor 
and LNM in 
18F-FDG-PET/CT was significantly higher as 
the T and N stage increased, while the tumor size was not 
significantly associated with the detection of LNM in 
18F-FDG-PET/CT. The histological subtype had a strong in-
fluence on the detection of primary tumor and LNM. The 
detection rate of SRC in 
18F-FDG-PET/CT was lower than 
that of non-SRC in terms of detection of primary tumor 
and LNM. The FDG uptake in primary tumor and LNM in 
cases of signet ring cell carcinoma was less pronounced 
than that in non-SRC [21,22]. The results suggest that 
18F-FDG-PET/CT appears to play a less useful diagnostic 
role in such cases. 
The evaluation of 
18F-FDG-PET/CT compared to MD-
CT in the diagnostic accuracy of EGC has not achieved 
consistent levels of accuracy. Previous reports have shown 
low detection rates for EGC in CT, with a range of 26 to 
53% [23,24]. In one study, the detection rate of mucosal 
cancer was very low (16.7%) in comparison to that for sub-
mucosal cancer (68.8%) in MDCT [25]. In the present 
study, the detection rate of mucosal cancer and sub-
mucosal cancer in 
18F-FDG-PET/CT was 35.0% (7/20) and 
58.8% (10/17), respectively, which is considerably higher 
detection rate for cases of mucosal cancer. From this result, 
18F-FDG-PET/CT displays greater superiority with respect 
to the detection of mucosal gastric cancer compared to 
MDCT, but has a limited role compared to other modal-
ities [26].
We found a borderline statistical significant positive 
correlation in SUVmax between the primary tumor and 
lymph node. The high SUVmax of primary tumor is asso-
ciated with better detection rate for LNM. High SUVmax in 
the primary tumor had a positive impact on the accuracy 
of 
18F-FDG-PET/CT assessment of LNM. Gastric cancer 
with SRC tended to be associated with a lower detection 
rate in both the primary tumor and LNM in 
18F-FDG- 
PET/CT, and 
18F-FDG-PET/CT may not be sufficient for 
preoperative staging in gastric cancer with SRC.
FDG-PET has a low to moderate sensitivity of LNM due 
to its limited resolution; FDG-PET have a 4- to 5-mm reso-
lution [27], but 14.5% of metastatic lymph node in gastric 
cancer has the largest diameter of less than 3 mm [28]. 
Another reason for the low sensitivity of FDG-PET is the 
masking of perigastric lymph node by the FDG uptake of 
the adjacent primary tumor. 
18F-FDG-PET/CT provides 
both anatomical and functional information and displays 
more accurate localization of both the primary tumor and 
lymph node with increased SUV than FDG-PET alone. We 
found that the sensitivity and specificity of 
18F-FDG- 
PET/CT in this study was comparable to a previous report 
in assessing lymph node status in gastric cancer (51.5% 
and 86.7% vs. 54.7% and 92.2%) [29]. 
The interesting finding from the present study was that 
both techniques had important informative role in pre-
operative staging of gastric cancer. 
18F-FDG-PET/CT was 
superior to MDCT in terms of the detection of the primary 




18F-FDG-PET/CT has a better diagnostic 
performance than MDCT in detecting a primary tumor in 
EGC and comparable accuracy of detecting LNM. Howev-
er, 
18F-FDG-PET/CT shows no definite improvement over 
MDCT in detecting primary tumors and LNM in patients 
with gastric cancer. Moreover, 
18F-FDG-PET/CT has clear Tae Kyung Ha, et al.
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limitations in preoperative staging in case of patients with 
SRC. This limitation must be taken into consideration 
when assessing gastric cancer. Therefore, randomized 
controlled trial on the application of 
18F-FDG-PET/CT in 
the diagnosis of EGC and AGC, respectively, is advocated.
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